| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5658741 | Gastroenterology | 2017 | 56 Pages |
Abstract
The combination tablet of elbasvir and grazoprevir, with or without ribavirin, was highly efficacious in inducing an SVR12 in patients with HCV genotype 1, 4, or 6 infection failed by previous treatment with peg-interferon and ribavirin, including patients with cirrhosis and/or a prior null response. The treatment was generally well tolerated. ClinicalTrials.gov Number: NCT02105701.
Keywords
Sensitivity thresholdRBVSAEsRAVALTElbasvirresistance-associated variantNGSSVREBRAlanine aminotransferaseRandomizedNext-generation sequencingTherapyAntiretroviral therapyRibavirinadverse eventserious adverse eventsconfidence intervalARTHepatitis CHepatitis C virusHCVhuman immunodeficiency virusHIVGenotypeGrazoprevir
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Paul Kwo, Edward J. Gane, Cheng-Yuan Peng, Brian Pearlman, John M. Vierling, Lawrence Serfaty, Maria Buti, Stephen Shafran, Paul Stryszak, Li Lin, Jacqueline Gress, Stuart Black, Frank J. Dutko, Michael Robertson, Janice Wahl, Lisa Lupinacci, Eliav Barr,